Physical Examination
She was an ill-looking child with low-grade fever. She was floppy and there were marked muscle weakness (proximal power 2/5 & distal power 3/5). There were periorbital symmetrical violaceous hue ( Figure 1 ) and Gottron's papules at the proximal interphalangeal joints of both hands ( Figure 2 ). Symmetrical non-blanchable papulosquamous erythema was also noted at her thighs ( Figure 3 ) and her limbs were tender and swollen. There were no dilated nail fold capillaries.
Investigations
Blood results showed ESR 116, CRP 14, CK 2802 (NR 2-134), LDH 2162 (NR 390-699), ANA=1:40 and negative anti-Jo-1, anti-Ro, anti-La, anti-RNP, anti-Sm, anti-dsDNA, RhF and ANCA. RFT, C3/C4, IgA & IgG levels were normal. Skin biopsy from left thigh showed patchy parakeratosis, basal layer spongiosis in epidermis and peri-capillary lymphocytic infiltrate in the superficial dermis. The impression was interface dermatitis, compatible with dermatomyositis. Muscle biopsy at left thigh showed non-specific myopathic changes with scattered atrophic type I and II fibres. 
Differential diagnosis
These include juvenile dermatomyositis, post-viral myositis (usually presents with exanthem and transient muscle weakness only), primary myopathies (usually do not have characteristic rash) and inflammatory myositis with other connective tissue diseases.
Diagnosis
The clinical and laboratory findings satisfied 2 out of 4 of the criteria for diagnosis of dermatomyositis (Table 1) . 1 The diagnosis of probable juvenile dermatomyositis was made.
Treatment and course
Prednisolone 2 mg/kg/day was started leading to prompt improvement of muscle power and fall in muscle enzymes. This was complicated by cytomegalovirus and parainfluenza virus type I pneumonitis. Subsequently, fulminant pseudomonas pneumonia and acute respiratory distress syndrome (ARDS) developed. Ventilation was required in mid-December, 1999. In view of fulminant chest infection complicating dermatomyositis, six courses of intravenous immunoglobulin were given weekly from late December till February. In March 2000, her power improved to 4/5 proximally and CK & LDH were normal. Prednisolone was reduced to 0.5 mg/kg/day alternate days. Skin rash resolved with pigmentation. However, attempts to wean off mechanical ventilation failed. There were significant lung parenchyma damage from fulminant chest infection and ARDS, and a tracheostomy was required. Despite multiple broadspectrum systemic antibiotics, the patient succumbed in April 2000 from severe pneumonia.
REVIEW ON JUVENILE DERMATOMYOSITIS

Definition and epidemiology
Juvenile Dermatomyositis (JDM) is a rare inflammatory myopathy with characteristic skin manifestations and muscular weakness. It is the commonest idiopathic inflammatory myopathies of childhood. 2 The incidence has been reported to be 3.2 per million populations with disease onset usually occurring between 5 and 14 years of age. Although the sexes are affected equally in the first decade of life, there is a female predominance thereafter. 3 It is exceptional for JDM to occur in infancy as in this patient.
Aetiology
The microvasculature appears to be the primary site of pathology in JDM. The aetiology of this small vessel injury is poorly understood, but possible causes include immune complex deposition, activation of terminal complement components, cytotoxic factors released from mononuclear cells, organ specific autoantibodies and infectious agents, especially enteroviruses. 3 Myositis specific antibodies (MSA), seen in 1/3 cases, targets cytoplasmic proteins and RNA in protein synthesis. 4 Its level precedes myositis and correlates with disease activity. Anti-Mi-2, one of MSA, is highly specific for dermatomyositis. Genetics may also contribute to development of JDM. Patients are found to have a strong association with HLA antigens B8/DR3. 3, 4 While adult dermatomyositis and JDM share most of the diagnostic skin features, JDM is associated with high incidence of calcinosis cutis, but not with underlying malignancy. It also has more features of vasculopathy.
Clinical presentation
The skin rash is usually of insidious onset and may precede myositis up to a year or more. However myositis occasionally precede skin rash by months instead; or alternatively the patient first presents with malaise and low-grade fever. Symmetrical proximal muscle weakness may present as fatigability with daily activities and at late stage may demonstrate Gower's sign. Muscle tenderness with or without anorexia may occur. Ten percent of cases also have dysphagia, dysphonia and dysponea suggesting oesophageal, palatal or pulmonary involvements.
Seventy percent of children develop the diagnostic rash with heliotropic periorbital macular erythema with or without oedema, Gottron's papules or patches, periungal erythema, confluent violaceous macular erythema at extensors of elbows, knees, upper trunk and atrophy. Some may have fibrosis and hypo-or 
Diagnosis
This is based on Bohan and Peter Criteria. Diagnosis is often delayed. The rash may be missed or misdiagnosed especially in pigmented skin. Muscle weakness may be misinterpreted as laziness and is difficult to demonstrate clinically if the child is uncooperative. Muscle enzymes are often normal at onset. Muscle biopsy and electromyography (EMG) may fail to show focal myopathy unless the involved muscle is investigated. As a result, the use of magnetic resonance imaging MRI (fat suppression sequence) has become increasingly important. It facilitates detection of focal inflammatory myopathy and directs the selection of a site of active inflammation for EMG and muscle biopsy. 2 One must remember, that MRI is sensitive but non-specific and non-diagnostic as prolonged muscle cramp, local trauma, strenuous exercise can give similar picture to inflammatory myopathies. Delay in therapy is strongly associated with an increased incidence of calcinosis.
Serologically, ANA is positive in 23% cases. Anti PM-1 and anti-Jo-1 are associated with interstitial pulmonary fibrosis and anti-Mi 2 with myositis. 3 Skin biopsy classically shows perivascular lymphocytic infiltrate, basal keratinocyte vacuolization, mucin deposit and epidermal atrophy indistinguishable from that of lupus erythematosus. In immunoflorescence study, C5b-9 complement deposition is seen in dermal vasculature and dermoepidermal junction of dermatomy ositis but not in systemic lupus erythematosus. 4 
Management and prognosis
Prompt diagnosis and early aggressive treatment best prevents complications. Disease flare can be detected with symptoms, raised LDH and AST. Corticosteroid (1-2 mg/kg/day) is the first line treatment. Pulse intravenous methylprednisolone is reserved in severe cases. Hydroxychloroquine (2-5 mg/kg/day) may help the rash but it does not reduce the need for systemic steroid. Other agents that have been used include methotrexate, azathioprine and low dose cyclosporin A. Intravenous Immunoglobulin has shown encouraging but inconsistent results. Aggressive treatment is usually not appropriate for children with skin signs but no active myositis. 3 Physical therapy is crucial to prevent contractures and disuse muscle atrophy. Calcinosis cutis is difficult to be treated but there were reports of improvement with diltiazem, warfarin and colchicine. Surgery is required for severe contractures. 4 Poor indicators of disease include initial treatment with low dose prednisolone, late onset of treatment, recalcitrant disease and pharyngeal involvement. Two thirds of children have severe complications from calcinosis and the mortality rate in United States is 3%. 4 
Learning points:
Early diagnosis and aggressive treatment of JDM best prevent complications, as delay in therapy is strongly associated with an increased incidence of calcinosis.
